Divarasib (GDC-6036) is an orally active, selective KRASG12C inhibitor with an IC50 of KRASG12C, occupies the switch II pocket, blocks GTP binding and SOS-mediated reactivation, and inhibits oncogenic KRAS signaling. Divarasib induces tumor shrinkage and robust tumor growth inhibition in KRASG12C-positive models and cancer cells. Divarasib can be used for the research of non-small cell lung cancer, colorectal adenocarcinoma, pancreatic ductal adenocarcinoma, and other KRASG12C-mutated solid tumors[1][2][3][4].
Molecular Weight:
622.06
Purity:
99.31
CAS Number:
[2417987-45-0]
Formula:
C29H32ClF4N7O2
Target:
Ras
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
